KEGG   DRUG: Spesolimab
Entry
D12066                      Drug                                   
Name
Spesolimab (USAN/INN);
Spesolimab (genetical recombination) (JAN);
Spesolimab-sbzo;
Spevigo (TN)
Product
Formula
C6480H9988N1736O2012S46
Exact mass
145787.9764
Mol weight
145878.0547
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYSFT SSWIHWVKQA PGQGLEWMGE INPGNVRTNY
NENFRNKVTM TVDTSISTAY MELSRLRSDD TAVYYCTVVF YGEPYFPYWG QGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPEAAGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(Light chain)
QIVLTQSPGT LSLSPGERAT MTCTASSSVS SSYFHWYQQK PGQAPRLWIY RTSRLASGVP
DRFSGSGSGT DFTLTISRLE PEDAATYYCH QFHRSPLTFG AGTKLEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H96, H146-H202, H222-L215, H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'96, H'146-H'202, H'222-L'215, H'263-H'323, H'369-H'427, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 3999
ATC code: L04AC22
Product: D12066<JP/US>
Efficacy
Antipsoriatic, Anti-IL-36 receptor antagonist
  Disease
Generalized pustular psoriasis [DS:H01663]
  Type
Monoclonal antibody
Comment
Treatment of immune and inflammatory disorders
Target
IL1RL2 (IL-36R) [HSA:8808] [KO:K05172]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC22 Spesolimab
      D12066  Spesolimab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Spesolimab
     D12066  Spesolimab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D12066  Spesolimab (USAN/INN); Spesolimab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D12066  Spesolimab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D12066  Spesolimab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL1RL2 (IL-36R)
     D12066  Spesolimab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12066
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12066
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12066
Other DBs
CAS: 2097104-58-8
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system